linjc16/ctgov huggingface dataset:
Vitamin D and the Influenza Epidemic

Study Overview
=================
Brief Summary
-----------------
Subjects included in ongoing vitamin d intervention trials were asked by questionnaire if they were ill with influenza during the winter season 2009/2010 to see if vitamin d supplementation prevented flu like disease.

Official Title
-----------------
Vitamin D and the Influenza Epidemic

Conditions
-----------------
Influenza

Intervention / Treatment
-----------------
* Drug: choleclaciferol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participant in vitamin D versus placebo study Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cholecalciferol<br>cholecalciferol in doses 800-6000 IU per day | Drug: choleclaciferol<br>* 800-6000 IU cholecalciferol per day<br>|
| Placebo Comparator: placebo<br>placebo identical looking as cholecalciferol capsules | Drug: choleclaciferol<br>* 800-6000 IU cholecalciferol per day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| influenza during the winter season 2009/2010 |  | up to 30 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D, influenza, prevention
Central Obesity and Disease Risk in Japanese Americans

Study Overview
=================
Brief Summary
-----------------
To conduct a longitudinal study of central obesity and related risk factors found to be associated with hypertension and atherosclerotic cardiovascular disease (ASCVD) in a previously-examined cross-sectional cohort of second-generation Japanese Americans and in a newly-recruited cohort of third generation Japanese Americans.

Detailed Description
-----------------
BACKGROUND: The study was conducted in response to a program announcment issued in 1991 on obesity and tests the hypothesis that atherosclerotic cardiovascular disease (ASCVD), hypertension, and/or non-insulin dependent diabetes mellitus (NIDDM) develop in Japanese Americans when there is a truncal pattern of weight gain (central adiposity), which is in turn accompanied by insulin resistance, hyperinsulinemia, and lipid abnormalities. This cluster of abnormalities has been called 'Syndrome X'. It is postulated that 'Syndrome X' develops in Japanese Americans in response to environmental (behavioral) factors, many of which reflect 'westernization' in this ethnic group. The research plan focuses upon the relationship between central obesity and metabolic changes and disease outcomes associated with 'Syndrome X' along with the behavioral variables that potential risk factors for the development of this cluster of abnormalities. DESIGN NARRATIVE: The cohort was re-examined for diabetes, hypertension, coronary heart, disease, peripheral vascular disease, and a number of potential coronary heart disease risk factors including medical history, health practice, social history, diet, glycosylated hemoglobin, insulin, proinsulin, c-peptide, glucose, anthrometric measurements, lipids, and computed tomography on the thorax, abdomen, and thigh.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Hypertension, Obesity, Diabetes Mellitus, Non-insulin Dependent, Hyperinsulinism, Insulin Resistance, Coronary Arteriosclerosis, Diabetes Mellitus, Metabolic Syndrome X

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Early Hydration in Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether hydration with sodium bicarbonate is more effective than hydration with sodium chloride to prevent contrast nephropathy in patients undergoing primary coronary intervention for acute ST elevation myocardial infarction.

Official Title
-----------------
Early Hydration in Acute Myocardial Infarction: Sodium Bicarbonate Versus Saline for the Prevention on Contrast-induced Acute Kidney Injury

Conditions
-----------------
Contrast Induced Acute Kidney Injury

Intervention / Treatment
-----------------
* Drug: sodium bicarbonate solution
* Drug: Isotonic saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients with AMI candidates for primary PCI presenting within 12 h of symptom onset with ST-segment elevation of more 1 mm in at least two contiguous leads of electrocardiogram. Exclusion Criteria: contrast medium administration within the 10 days end-stage renal failure requiring dialysis refusal to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sodium bicarbonate<br>Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure | Drug: sodium bicarbonate solution<br> <br> * Other names: 154 mEq/L in dextrose and H2O;|
| Active Comparator: Saline<br>Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure | Drug: Isotonic saline<br> <br> * Other names: 0.9% sodium chloride;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of contrast-induced acute kidney injury | contrast-induced acute kidney injury is defined as an increase in serum creatinine >= 0.3 mg/dL over the baseline value within 2 days after the administration of the contrast medium | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse clinical events | adverse clinical events within 1 month including in-hospital death and need for dialysis or hemofiltration | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Contrast-induced nephropathy, Contrast media, Angiography, Coronary percutaneous intervention
The Influence of Cessation of Pomegranate Juice Intake on Inflammation and Oxidative Stress Markers and Glucose Control in Diabetic and Non Diabetic Chronic Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
The current study will investigate chronic hemodialysis patients who were treated in our unit with pomegranate juice intake for 1 year - compared to a control group. Markers will be taken 3 months after cessation of pomegranate juice intake, for inflammation and oxidative stress and Hb A1c.

Conditions
-----------------
Inflammation, Oxidative Stress

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic Hemodialysis patients three months after termination of study which is currently carried out at our unit; which compared patients taking pomegranate juice three times a week for 1 year to a group that received placebo juice. Exclusion Criteria: Patients who do not currently participate in above mentioned trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| chronic Hemodialysis patients, treated in our unit.<br> | Other: No intervention<br> <br> |
| chronic Hemodialysis patients , No intervention<br>chronic Hemodialysis patients, treated in our unit. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammation, Oxidative stress, HbA1c, Hemodialysis
Vitamin D Levels and Postoperative Pain in Laparoscopic Cholecystectomy

Study Overview
=================
Brief Summary
-----------------
The deficiency of vitamin D is common in patients with gastrointestinal system disorders. Vitamin D has been associated with chronic non-specific musculoskeletal pain and migraines due to anti-inflammatory effects. This prospective observational study will undergo elective laparoscopic cholecystectomy surgery between 18 and 65 years, is planned to participate in ASA (American Society of Anesthesiologists) 1-3, 90 volunteer patients. In preoperative evaluation, the remaining 3 ml of blood was centrifuged from the routine received blood to determine the level of vitamin D will be kept. Postoperative will be applied to patient controlled analgesia to all patients for 24 hours. To determine the level of postoperative pain, the visual analog scale (VAS) will be used in the clock unit and at the service 6, 12 and 24 hours. In this study, the investigators aimed to test the hypothesis of relation to pain and opioid consumption in acute postoperative (24 hours) of perioperative low-vitamin D.

Official Title
-----------------
Effect of Vitamin D Levels on Postoperative Pain and Narcotic Analgesia in Patients With Laparoscopic Cholecystectomy

Conditions
-----------------
Vitamin D Deficiency, Postoperative Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteer, Between the Ages Of 18-65, Least Primary School Graduate, Not Using Drugs That May Affect Cognitive Functions, Non-Alcohol Substance Use, Patients Without Psychiatric and Neurological Disease. Exclusion Criteria: Those with known psychiatric disease and drugs, Those with an important cardiovascular or central nervous system disease, Patients with pain syndromes or routinely using opioid. Very urgent patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preoperative Vitamin D Level and postoperative pain in patients to undergo laparoscopic cholecystectomy operation | Correlations of preoperative Vitamin D Level between postoperative pain in patients undergoing laparoscopic cholecystectomy.to undergo laparoscopic cholecystectomy operation | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preoperative Vitamin D Level and opioid analgesic consumption | Correlations of preoperative Vitamin D Level between opioid analgesic consumption in patients undergoing laparoscopic cholecystectomy.to undergo laparoscopic cholecystectomy operation | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopic cholecystectomy, Vitamin D Deficiency, Postoperative Pain
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
Survivors of childhood cancer have an increased risk of death from cardiovascular disease due to both the therapies they received while undergoing treatment and diet and lifestyle factors. The nature of cardiovascular risk and the interaction between treatment affects and cardiovascular risk factors is unknown. We propose to study vascular inflammatory markers as well as measure of blood vessel stiffness (both of which are predictive of early heart disease) in 100 pediatric cancer survivors and 100 control children. Characterization of vascular inflammation and stiffness in long-term survivors will allow for the development of future interventions to decrease inflammation through both pharmacologic and lifestyle modifications.

Official Title
-----------------
Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors

Conditions
-----------------
Cancer Survivor, Pediatric Cancer

Intervention / Treatment
-----------------
* Procedure: Blood specimen
* Procedure: Echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6-30 years of age 2 years from the completion of therapy for cancer free of active disease Exclusion Criteria: <6 or > 30 years of age current cancer treatment or inside of 2 years post treatment Active disease/infection

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention procedures<br>All the procedures will be completed for every subject | Procedure: Blood specimen<br> <br> Procedure: Echocardiography<br> <br> * Other names: Bone Mineral Density;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular Inflammation | All study procedures to assess vascular inflammation will be assessed through specimen sample collection and through procedures such as (echocardiograph) | single time point at initial visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer survivors, Long-term cancer survivor
Changes in Tissue Oxygenation Following Regional Anesthesia

Study Overview
=================
Brief Summary
-----------------
Adequate tissue oxygenation is required for effective white blood cell function and bactericidal activity. Decreased tissue oxygenation is a risk factor for perioperative wound infections. Regional anesthetic techniques result in a functional sympathetic block and may increase tissue oxygenation. The purpose of this study is to evaluate changes in tissue oxygenation using a non-invasive Near-infrared spectroscopy (NIRS) device. The current study will evaluate changes in tissue oxygenation following regional anesthetic techniques (peripheral nerve blockade and neuraxial techniques such as caudal block) in pediatric patients). Regional anesthesia will induce a sympathetic blockade and improve tissue oxygenation.

Official Title
-----------------
Changes in Tissue Oxygenation Following Regional Anesthesia

Conditions
-----------------
Anesthesia, Local

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing a surgical procedure who have consented to a regional block. Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Non-invasive near infra-red device (NIRS)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tissue oxygenation | NIRS values from two sites before and after the regional anesthetic is placed. | 1 Day (Day of Surgery) |
The Electroencephalogram Analysis in the Differences Between Inhalation Anesthetic and Propofol.

Study Overview
=================
Brief Summary
-----------------
The investigators will record 120 patients who received general anesthesia, their EEG data recorded from Bispectral Index (BIS) machine for emperical mode decomposition (EMD) analysis, the investigators decomposed EEG signal to different oscillations and tried to observe the differences between hypnotic medications through EEG analysis.

Detailed Description
-----------------
The electroencephalography (EEG) is a noninvasive medical technique for monitoring and recording the electrical activity of brain. The Hilbert-Huang transform (HHT) was proposed to decompose EEG signal into intrinsic mode functions (IMF) which can obtain instantaneous frequency data and work well for data that is nonstationary and nonlinear. The relationship between frontal EEG patterns and hypnotics remain poorly understood. The investigators only can tell the increase in frontal EEG power and shift power to lower frequencies during general anesthesia from publications. The investigators are going to decompose EEG with HHT and find the energy shift during general anesthesia, compare with different anesthetics. The investigators will record 120 patients who received general anesthesia, their EEG data recorded from BIS machine for EMD analysis, the investigators decomposed EEG signal to different oscillations and tried to observe the differences between hypnotic medications through EEG analysis.

Official Title
-----------------
The Electroencephalogram Analysis in the Differences Between Inhalation Anesthetic and Propofol.

Conditions
-----------------
Sevoflurane, Propofol

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II scheduled surgery who need general anesthesia Exclusion Criteria: allergy to the BIS patch not suitable for general anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The gamma, beta, alpha and theta power of EEG | We will try to observe the differences between hypnotic medications through EEG decomposed and power analysis. | the total duration inclusions in operation room |
Children, Perennial Allergic Rhinitis (PAR), l-t Growth

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.

Official Title
-----------------
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Long-Term Treatment With Rhinocort Aqua (Budesonide) Nasal Spray in Children With Perennial Allergic Rhinitis.

Conditions
-----------------
Perennial Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: Budesonide
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids. A documented history of at least one year of perennial allergic rhinitis. A positive response to a skin prick test for perennial allergens that must be present in the subject's environment. Height and weight within normal limits. Exclusion Criteria: Any disease which may affect growth Sexual development later than Tanner stage I. Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Budesonide | Drug: Budesonide<br> <br> * Other names: Rhinocort AQUA;|
| Placebo Comparator: 2<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in height over a 12 month period |  | 3 monthly | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in growth velocity over a 12 month period. |  | 3 monthly | 
| Other safety - assessed by adverse event query |  | 3 monthly | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allergic rhinitis, Perennial allergic rhinitis, Paediatric, Growth, budesonide, Rhinocort AQUA